Gyre Therapeutics, Inc. - Common Stock (NQ:GYRE)

7.380 +0.270 (+3.80%)

Delayed Quote Updated: 3:18 PM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Gyre Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 Next >

Ross Stores, Deckers Outdoor, Xerox Holdings And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗

May 23, 2025

Via Benzinga

Discover the top movers in Friday's pre-market session. ↗

May 23, 2025

As the US market prepares to open on Friday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.

Via Chartmill

Gyre Therapeutics Announces Pricing of $20.0 Million Public Offering of Common Stock

May 22, 2025

From Gyre Therapeutics Inc.

Via GlobeNewswire

GYRE Stock Earnings: Gyre Therapeutics Reported Results for Q2 2024 ↗

August 13, 2024

Gyre Therapeutics just reported results for the second quarter of 2024.

Via InvestorPlace

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

May 22, 2025

Via Benzinga

Thursday's after hours session: top gainers and losers ↗

May 22, 2025

After the conclusion of the US market's regular session on Thursday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers.

Via Chartmill

Gyre Therapeutics Announces Proposed Underwritten Public Offering of Common Stock

May 22, 2025

From Gyre Therapeutics Inc.

Via GlobeNewswire

Gyre Therapeutics’ Hydronidone Met the Primary Endpoint and Demonstrated Statistically Significant Fibrosis Regression in Pivotal Phase 3 Trial for the Treatment of CHB-associated Liver Fibrosis in China

May 22, 2025

From Gyre Therapeutics Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

May 12, 2025

Via Benzinga

Gyre Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

May 09, 2025

Net Income of $3.7 million; reaffirms Full-Year Revenue Guidance of $118–$128 million

From Gyre Therapeutics Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

April 14, 2025

Via Benzinga

Discover the top movers in Monday's pre-market session. ↗

April 07, 2025

Before the US market kicks off on Monday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers.

Via Chartmill

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

April 07, 2025

Via Benzinga

Cognyte Software Posts Upbeat Results, Joins AngioDynamics, Allegiant Travel And Other Big Stocks Moving Higher On Wednesday ↗

April 02, 2025

Via Benzinga

Gyre Therapeutics Announces NMPA Approval for Clinical Trial Evaluating Pirfenidone Capsules in Oncology-Related Pulmonary Complications

March 31, 2025

From Gyre Therapeutics Inc.

Via GlobeNewswire

Gyre Therapeutics Announces Publication of Protocol for Phase 3 Trial Evaluating F351 for CHB-Associated Liver Fibrosis in Journal of Clinical and Translational Hepatology

March 27, 2025

From Gyre Therapeutics Inc.

Via GlobeNewswire

S&P 500 Down 1%; Sarepta Therapeutics Shares Plunge ↗

March 18, 2025

Via Benzinga

Topics Stocks

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

March 18, 2025

Via Benzinga

Gyre Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

March 17, 2025

From Gyre Therapeutics Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

March 13, 2025

Via Benzinga

Gyre Therapeutics Announces the Appointment of Ping Zhang to Board of Directors

January 06, 2025

From Gyre Therapeutics, Inc.

Via GlobeNewswire

Gyre Therapeutics Reports Third Quarter 2024 and Year-To-Date Financial Results and Provides Business Update

November 13, 2024

From Gyre Therapeutics, Inc.

Via GlobeNewswire

Gyre Therapeutics Announces Last Patient Completed Pivotal Phase 3 Trial Evaluating F351 for CHB-Associated Liver Fibrosis

October 22, 2024

From Gyre Therapeutics, Inc.

Via GlobeNewswire

Gyre Therapeutics to Present at 8th Annual H.C. Wainwright MASH Investor Conference

October 01, 2024

From Gyre Therapeutics, Inc.

Via GlobeNewswire

Applied Therapeutics, PowerFleet, VF Corp, Victoria's Secret And Other Big Stocks Moving Higher On Wednesday ↗

September 18, 2024

Via Benzinga

Gyre Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference

September 04, 2024

From Gyre Therapeutics, Inc.

Via GlobeNewswire

Galapagos, XPeng, CorMedix And Other Big Stocks Moving Higher On Monday ↗

August 26, 2024

Via Benzinga

Gyre Therapeutics Reports Second Quarter 2024 and Year-To-Date Financial Results and Provides Business Update

August 13, 2024

From Gyre Therapeutics, Inc.

Via GlobeNewswire

Gyre Therapeutics to Present at Sidoti Virtual Investor Conference

August 09, 2024

From Gyre Therapeutics, Inc.

Via GlobeNewswire

Gyre Therapeutics Announces Appointment of David M. Epstein, Ph.D., to Board of Directors

August 08, 2024

From Gyre Therapeutics, Inc.

Via GlobeNewswire

< Previous 1 2 3 4 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.